Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for BCAX is 32.77M, and currently, short sellers hold a 19.82% ratio of that floaft. The average trading volume of BCAX on May 23, 2025 was 582.43K shares.
BCAX) stock’s latest price update
Bicara Therapeutics Inc (NASDAQ: BCAX) has experienced a rise in its stock price by 7.33 compared to its previous closing price of 14.59. However, the company has seen a gain of 8.22% in its stock price over the last five trading days. globenewswire.com reported 2025-05-22 that Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset
BCAX’s Market Performance
BCAX’s stock has risen by 8.22% in the past week, with a monthly rise of 0.97% and a quarterly rise of 20.46%. The volatility ratio for the week is 4.82% while the volatility levels for the last 30 days are 5.71% for Bicara Therapeutics Inc The simple moving average for the last 20 days is 10.73% for BCAX’s stock, with a simple moving average of -7.23% for the last 200 days.
Analysts’ Opinion of BCAX
Many brokerage firms have already submitted their reports for BCAX stocks, with Wells Fargo repeating the rating for BCAX by listing it as a “Underweight.” The predicted price for BCAX in the upcoming period, according to Wells Fargo is $8 based on the research report published on April 17, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see BCAX reach a price target of $31. The rating they have provided for BCAX stocks is “Outperform” according to the report published on February 06th, 2025.
H.C. Wainwright gave a rating of “Buy” to BCAX, setting the target price at $42 in the report published on December 06th of the previous year.
BCAX Trading at 19.37% from the 50-Day Moving Average
After a stumble in the market that brought BCAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.25% of loss for the given period.
Volatility was left at 5.71%, however, over the last 30 days, the volatility rate increased by 4.82%, as shares surge +0.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.37% upper at present.
During the last 5 trading sessions, BCAX rose by +8.22%, in comparison to the 20-day moving average, which settled at $14.14. In addition, Bicara Therapeutics Inc saw -10.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCAX starting from Meisner Lara, who sale 79,146 shares at the price of $12.90 back on Mar 14 ’25. After this action, Meisner Lara now owns 0 shares of Bicara Therapeutics Inc, valued at $1,021,211 using the latest closing price.
LARA S. MEISNER, the Officer of Bicara Therapeutics Inc, proposed sale 79,146 shares at $13.35 during a trade that took place back on Mar 14 ’25, which means that LARA S. MEISNER is holding shares at $1,056,599 based on the most recent closing price.
Stock Fundamentals for BCAX
The total capital return value is set at -0.23.
Based on Bicara Therapeutics Inc (BCAX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -150.78.
Currently, EBITDA for the company is -67.75 million with net debt to EBITDA at 4.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 24.62.
Conclusion
In a nutshell, Bicara Therapeutics Inc (BCAX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
